For 2012, analysts are expecting 2.2% sales growth on EPS of $5.13, which is the middle of Johnson & Johnson's guidance.
Even if the company's results are at the top of its range, one has to wonder whether it will be enough to compel investors to buy the stock.
At the time of publication, the author held no positions in any of the stocks mentioned.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts